{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T17:42:25Z","timestamp":1792086145379,"version":"4.4.0"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Gansu Province Key research and development Program Project","award":["24YFFA046"],"award-info":[{"award-number":["24YFFA046"]}]},{"name":"Cuiying Technology Innovation Program Project of Lanzhou University Second Hospital","award":["CY2024-MS-B13"],"award-info":[{"award-number":["CY2024-MS-B13"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82360029"],"award-info":[{"award-number":["82360029"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-17422-2","type":"journal-article","created":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T13:19:51Z","timestamp":1758806391000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Peroxiredoxins as novel indicators in multiple myeloma associated with ferroptosis and immune infiltration"],"prefix":"10.1038","volume":"15","author":[{"given":"Yue","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohuan","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuxi","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liansheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,25]]},"reference":[{"key":"17422_CR1","first-page":"7","volume":"66","author":"RL Siegel","year":"2016","unstructured":"Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics. CA Cancer J. Clin. 66, 7\u201330 (2016).","journal-title":"CA Cancer J Clin"},{"key":"17422_CR2","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41408-020-0284-7","volume":"10","author":"CR Marinac","year":"2020","unstructured":"Marinac, C. R., Ghobrial, I. M., Birmann, B. M., Soiffer, J. & Rebbeck, T. R. Dissecting racial disparities in multiple myeloma. Blood Cancer J 10, 19 (2020).","journal-title":"Blood Cancer J"},{"key":"17422_CR3","doi-asserted-by":"publisher","first-page":"375","DOI":"10.5694\/mja2.50129","volume":"210","author":"DE Joshua","year":"2019","unstructured":"Joshua, D. E., Bryant, C., Dix, C., Gibson, J. & Ho, J. Biology and therapy of multiple myeloma. Med. J. Aust. 210, 375\u2013380 (2019).","journal-title":"Med. J. Aust."},{"key":"17422_CR4","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1182\/blood-2018-03-840132","volume":"132","author":"BA Walker","year":"2018","unstructured":"Walker, B. A. et al. Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma. Blood 132, 587\u2013597 (2018).","journal-title":"Blood"},{"key":"17422_CR5","doi-asserted-by":"publisher","first-page":"11430","DOI":"10.3390\/ijms222111430","volume":"22","author":"M Gavriatopoulou","year":"2021","unstructured":"Gavriatopoulou, M., Paschou, S. A., Ntanasis-Stathopoulos, I. & Dimopoulos, M. A. Metabolic disorders in multiple myeloma. Int. J. Mol. Sci. 22, 11430 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"17422_CR6","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s10555-020-09943-1","volume":"40","author":"KS Opperman","year":"2021","unstructured":"Opperman, K. S., Vandyke, K., Psaltis, P. J., Noll, J. E. & Zannettino, A. C. W. Macrophages in multiple myeloma: Key roles and therapeutic strategies. Cancer Metastasis Rev. 40, 273\u2013284 (2021).","journal-title":"Cancer Metastasis Rev."},{"key":"17422_CR7","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s10555-017-9698-5","volume":"36","author":"JJ Driscoll","year":"2017","unstructured":"Driscoll, J. J. & Brailey, M. Emerging small molecule approaches to enhance the antimyeloma benefit of proteasome inhibitors. Cancer Metastasis Rev. 36, 585\u2013598 (2017).","journal-title":"Cancer Metastasis Rev."},{"key":"17422_CR8","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1038\/s41375-018-0362-z","volume":"33","author":"T Harding","year":"2019","unstructured":"Harding, T., Baughn, L., Kumar, S. & Van Ness, B. The future of myeloma precision medicine: Integrating the compendium of known drug resistance mechanisms with emerging tumor profiling technologies. Leukemia 33, 863\u2013883 (2019).","journal-title":"Leukemia"},{"key":"17422_CR9","doi-asserted-by":"publisher","first-page":"e2400269","DOI":"10.1002\/ardp.202400269","volume":"357","author":"R Rocca","year":"2024","unstructured":"Rocca, R. et al. TERRA G-quadruplex stabilization behind the anti-multiple myeloma activity: Novel insights about resveratrol pleiotropic effects. Arch Pharm. (Weinheim) 357, e2400269 (2024).","journal-title":"Arch Pharm. (Weinheim)"},{"key":"17422_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.112950","volume":"141","author":"X Zhang","year":"2024","unstructured":"Zhang, X. et al. Epigallocatechin gallate induces apoptosis in multiple myeloma cells through endoplasmic reticulum stress induction and cytoskeletal disruption. Int. Immunopharmacol. 141, 112950 (2024).","journal-title":"Int. Immunopharmacol."},{"key":"17422_CR11","doi-asserted-by":"publisher","first-page":"7284","DOI":"10.3390\/ijms25137284","volume":"25","author":"S Isola","year":"2024","unstructured":"Isola, S. et al. Vitamin C supplementation in the treatment of autoimmune and onco-hematological diseases: From prophylaxis to adjuvant therapy. Int. J. Mol. Sci. 25, 7284 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"17422_CR12","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.redox.2014.11.002","volume":"4","author":"K Salem","year":"2015","unstructured":"Salem, K., McCormick, M. L., Wendlandt, E., Zhan, F. & Goel, A. Copper-zinc superoxide dismutase-mediated redox regulation of bortezomib resistance in multiple myeloma. Redox Biol. 4, 23\u201333 (2015).","journal-title":"Redox Biol."},{"key":"17422_CR13","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/nature10189","volume":"475","author":"GM DeNicola","year":"2011","unstructured":"DeNicola, G. M. et al. Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature 475, 106\u2013109 (2011).","journal-title":"Nature"},{"key":"17422_CR14","doi-asserted-by":"publisher","DOI":"10.1098\/rsob.120144","volume":"3","author":"J Watson","year":"2013","unstructured":"Watson, J. Oxidants, antioxidants and the current incurability of metastatic cancers. Open Biol. 3, 120144 (2013).","journal-title":"Open Biol."},{"key":"17422_CR15","doi-asserted-by":"publisher","first-page":"10829","DOI":"10.1021\/acs.chemrev.9b00371","volume":"119","author":"A Zeida","year":"2019","unstructured":"Zeida, A. et al. Catalysis of peroxide reduction by fast reacting protein thiols. Chem. Rev. 119, 10829\u201310855 (2019).","journal-title":"Chem. Rev."},{"key":"17422_CR16","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1002\/prot.22936","volume":"79","author":"KJ Nelson","year":"2011","unstructured":"Nelson, K. J. et al. Analysis of the peroxiredoxin family: Using active-site structure and sequence information for global classification and residue analysis. Proteins 79, 947\u2013964 (2011).","journal-title":"Proteins"},{"key":"17422_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pharmthera.2016.03.018","volume":"163","author":"MH Park","year":"2016","unstructured":"Park, M. H., Jo, M., Kim, Y. R., Lee, C.-K. & Hong, J. T. Roles of peroxiredoxins in cancer, neurodegenerative diseases and inflammatory diseases. Pharmacol. Ther. 163, 1\u201323 (2016).","journal-title":"Pharmacol. Ther."},{"key":"17422_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.56","volume":"8","author":"L Komorowski","year":"2024","unstructured":"Komorowski, L. et al. Concomitant inhibition of the thioredoxin system and nonhomologous DNA repair potently sensitizes Philadelphia-positive lymphoid leukemia to tyrosine kinase inhibitors. Hemasphere 8, e56 (2024).","journal-title":"Hemasphere"},{"key":"17422_CR19","doi-asserted-by":"publisher","first-page":"7863","DOI":"10.1038\/s41598-024-58216-2","volume":"14","author":"A De Bol\u00f2s","year":"2024","unstructured":"De Bol\u00f2s, A. et al. SOX11\/PRDX2 axis modulates redox homeostasis and chemoresistance in aggressive mantle cell lymphoma. Sci. Rep. 14, 7863 (2024).","journal-title":"Sci. Rep."},{"key":"17422_CR20","doi-asserted-by":"publisher","first-page":"2698","DOI":"10.1182\/blood-2017-10-813139","volume":"131","author":"M Ying","year":"2018","unstructured":"Ying, M. et al. Ubiquitin-dependent degradation of CDK2 drives the therapeutic differentiation of AML by targeting PRDX2. Blood 131, 2698\u20132711 (2018).","journal-title":"Blood"},{"key":"17422_CR21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0016340","volume":"6","author":"KK Palande","year":"2011","unstructured":"Palande, K. K. et al. The antioxidant protein peroxiredoxin 4 is epigenetically down regulated in acute promyelocytic leukemia. PLoS ONE 6, e16340 (2011).","journal-title":"PLoS ONE"},{"key":"17422_CR22","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1016\/j.freeradbiomed.2009.06.018","volume":"47","author":"K Abbas","year":"2009","unstructured":"Abbas, K. et al. Signaling events leading to peroxiredoxin 5 up-regulation in immunostimulated macrophages. Free Radic. Biol. Med. 47, 794\u2013802 (2009).","journal-title":"Free Radic. Biol. Med."},{"key":"17422_CR23","doi-asserted-by":"publisher","first-page":"881","DOI":"10.3390\/antiox13070881","volume":"13","author":"DJ Lagal","year":"2024","unstructured":"Lagal, D. J. et al. Tumoral malignancy decreases coupled with higher ROS and lipid peroxidation in HCT116 colon cancer cells upon loss of PRDX6. Antioxidants (Basel) 13, 881 (2024).","journal-title":"Antioxidants (Basel)"},{"key":"17422_CR24","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1158\/1535-7163.MCT-09-0904","volume":"9","author":"J-N Ho","year":"2010","unstructured":"Ho, J.-N. et al. Phospholipase A2 activity of peroxiredoxin 6 promotes invasion and metastasis of lung cancer cells. Mol. Cancer Ther. 9, 825\u2013832 (2010).","journal-title":"Mol. Cancer Ther."},{"key":"17422_CR25","doi-asserted-by":"publisher","first-page":"btae615","DOI":"10.1093\/bioinformatics\/btae615","volume":"40","author":"BT Sherman","year":"2024","unstructured":"Sherman, B. T., Panzade, G., Imamichi, T. & Chang, W. DAVID Ortholog: An integrative tool to enhance functional analysis through orthologs. Bioinformatics 40, btae615 (2024).","journal-title":"Bioinformatics"},{"key":"17422_CR26","doi-asserted-by":"publisher","first-page":"D330","DOI":"10.1093\/nar\/gky1055","volume":"47","author":"The Gene Ontology Consortium","year":"2019","unstructured":"The Gene Ontology Consortium. The gene ontology resource: 20 years and still GOing strong. Nucleic Acids Res 47, D330\u2013D338 (2019).","journal-title":"Nucleic Acids Res"},{"key":"17422_CR27","doi-asserted-by":"publisher","first-page":"D353","DOI":"10.1093\/nar\/gkw1092","volume":"45","author":"M Kanehisa","year":"2017","unstructured":"Kanehisa, M., Furumichi, M., Tanabe, M., Sato, Y. & Morishima, K. KEGG: New perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res 45, D353\u2013D361 (2017).","journal-title":"Nucleic Acids Res"},{"key":"17422_CR28","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 102, 15545\u201315550 (2005).","journal-title":"Proc Natl Acad Sci U S A"},{"key":"17422_CR29","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nmeth.3337","volume":"12","author":"AM Newman","year":"2015","unstructured":"Newman, A. M. et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods 12, 453\u2013457 (2015).","journal-title":"Nat Methods"},{"key":"17422_CR30","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s00428-013-1433-1","volume":"463","author":"APD Demasi","year":"2013","unstructured":"Demasi, A. P. D. et al. Expression of peroxiredoxins I and IV in multiple myeloma: Association with immunoglobulin accumulation. Virchows Arch 463, 47\u201355 (2013).","journal-title":"Virchows Arch"},{"key":"17422_CR31","doi-asserted-by":"publisher","first-page":"391","DOI":"10.3727\/096504011X13127606672922","volume":"19","author":"L Ren","year":"2011","unstructured":"Ren, L. et al. The role of peroxiredoxin V in (-)-epigallocatechin 3-gallate-induced multiple myeloma cell death. Oncol Res 19, 391\u2013398 (2011).","journal-title":"Oncol Res"},{"key":"17422_CR32","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/s41598-024-84021-y","volume":"15","author":"D Gao","year":"2025","unstructured":"Gao, D. et al. Peroxiredoxin 6 maintains mitochondrial homeostasis and promotes tumor progression through ROS\/JNK\/p38 MAPK signaling pathway in multiple myeloma. Sci. Rep. 15, 70 (2025).","journal-title":"Sci. Rep."},{"key":"17422_CR33","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1002\/ajh.26080","volume":"96","author":"S Bal","year":"2021","unstructured":"Bal, S., Giri, S., Godby, K. N. & Costa, L. J. New regimens and directions in the management of newly diagnosed multiple myeloma. Am. J. Hematol. 96, 367\u2013378 (2021).","journal-title":"Am. J. Hematol."},{"key":"17422_CR34","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1038\/leu.2017.219","volume":"31","author":"S Hipp","year":"2017","unstructured":"Hipp, S. et al. A novel BCMA\/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo. Leukemia 31, 2278 (2017).","journal-title":"Leukemia"},{"key":"17422_CR35","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41571-020-0427-6","volume":"18","author":"L Mikkilineni","year":"2021","unstructured":"Mikkilineni, L. & Kochenderfer, J. N. CAR T cell therapies for patients with multiple myeloma. Nat Rev. Clin. Oncol. 18, 71\u201384 (2021).","journal-title":"Nat Rev. Clin. Oncol."},{"key":"17422_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2019.100663","volume":"48","author":"S Narayanan","year":"2020","unstructured":"Narayanan, S. et al. Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance. Drug Resist Updat 48, 100663 (2020).","journal-title":"Drug Resist Updat"},{"key":"17422_CR37","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1007\/s11864-024-01273-6","volume":"25","author":"F Li","year":"2024","unstructured":"Li, F., Liu, J. & Fu, Y. Acquired bortezomib resistance in multiple myeloma: From mechanisms to strategy. Curr. Treat Options Oncol. 25, 1354\u20131365 (2024).","journal-title":"Curr. Treat Options Oncol."},{"key":"17422_CR38","doi-asserted-by":"publisher","first-page":"2469","DOI":"10.1111\/j.1742-4658.2009.06985.x","volume":"276","author":"A Hall","year":"2009","unstructured":"Hall, A., Karplus, P. A. & Poole, L. B. Typical 2-Cys peroxiredoxins\u2013structures, mechanisms and functions. FEBS J. 276, 2469\u20132477 (2009).","journal-title":"FEBS J."},{"key":"17422_CR39","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/S0968-0004(02)00003-8","volume":"28","author":"ZA Wood","year":"2003","unstructured":"Wood, Z. A., Schr\u00f6der, E., Robin Harris, J. & Poole, L. B. Structure, mechanism and regulation of peroxiredoxins. Trends Biochem. Sci. 28, 32\u201340 (2003).","journal-title":"Trends Biochem. Sci."},{"key":"17422_CR40","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.3324\/haematol.2011.043612","volume":"96","author":"L De Franceschi","year":"2011","unstructured":"De Franceschi, L. et al. Oxidative stress modulates heme synthesis and induces peroxiredoxin-2 as a novel cytoprotective response in \u03b2-thalassemic erythropoiesis. Haematologica 96, 1595\u20131604 (2011).","journal-title":"Haematologica"},{"key":"17422_CR41","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1111\/j.1601-0825.2008.01455.x","volume":"14","author":"APD Demasi","year":"2008","unstructured":"Demasi, A. P. D. et al. Peroxiredoxin I is differentially expressed in multiple myelomas and in plasmablastic lymphomas. Oral Dis. 14, 741\u2013746 (2008).","journal-title":"Oral Dis."},{"key":"17422_CR42","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.chembiol.2020.03.013","volume":"27","author":"BR Stockwell","year":"2020","unstructured":"Stockwell, B. R. & Jiang, X. The chemistry and biology of ferroptosis. Cell Chem. Biol. 27, 365\u2013375 (2020).","journal-title":"Cell Chem. Biol."},{"key":"17422_CR43","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/s41419-020-2298-2","volume":"11","author":"J Li","year":"2020","unstructured":"Li, J. et al. Ferroptosis: Past, present and future. Cell Death Dis 11, 88 (2020).","journal-title":"Cell Death Dis"},{"key":"17422_CR44","doi-asserted-by":"publisher","first-page":"4952857","DOI":"10.1155\/2023\/4952857","volume":"2023","author":"P Chen","year":"2023","unstructured":"Chen, P., Chen, Z., Zhai, J., Yang, W. & Wei, H. Overexpression of PRDX2 in adipose-derived mesenchymal stem cells enhances the therapeutic effect in a neurogenic erectile dysfunction rat model by inhibiting ferroptosis. Oxid Med. Cell Longev. 2023, 4952857 (2023).","journal-title":"Oxid Med. Cell Longev."},{"key":"17422_CR45","doi-asserted-by":"publisher","first-page":"3931","DOI":"10.1016\/j.molcel.2023.09.025","volume":"83","author":"S Cui","year":"2023","unstructured":"Cui, S. et al. Identification of hyperoxidized PRDX3 as a ferroptosis marker reveals ferroptotic damage in chronic liver diseases. Mol. Cell 83, 3931-3939.e5 (2023).","journal-title":"Mol. Cell"},{"key":"17422_CR46","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1186\/s12885-025-14173-1","volume":"25","author":"C Lin","year":"2025","unstructured":"Lin, C., Xie, S., Wang, M. & Shen, J. PRDX1 knockdown promotes erastin-induced ferroptosis and impedes diffuse large B-cell lymphoma development by inhibiting the MAPK\/ERK pathway. BMC Cancer 25, 806 (2025).","journal-title":"BMC Cancer"},{"key":"17422_CR47","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1038\/leu.2016.346","volume":"31","author":"J Bordini","year":"2017","unstructured":"Bordini, J. et al. Induction of iron excess restricts malignant plasma cells expansion and potentiates bortezomib effect in models of multiple myeloma. Leukemia 31, 967\u2013970 (2017).","journal-title":"Leukemia"},{"key":"17422_CR48","doi-asserted-by":"publisher","first-page":"971","DOI":"10.3324\/haematol.2012.074872","volume":"98","author":"A Campanella","year":"2013","unstructured":"Campanella, A. et al. Iron increases the susceptibility of multiple myeloma cells to bortezomib. Haematologica 98, 971\u2013979 (2013).","journal-title":"Haematologica"},{"key":"17422_CR49","doi-asserted-by":"publisher","first-page":"970","DOI":"10.3390\/cancers12040970","volume":"12","author":"J Bordini","year":"2020","unstructured":"Bordini, J. et al. Iron causes lipid oxidation and inhibits proteasome function in multiple myeloma cells: A proof of concept for novel combination therapies. Cancers (Basel) 12, 970 (2020).","journal-title":"Cancers (Basel)"},{"key":"17422_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.118077","volume":"260","author":"Y Zhong","year":"2020","unstructured":"Zhong, Y. et al. FTY720 induces ferroptosis and autophagy via PP2A\/AMPK pathway in multiple myeloma cells. Life Sci. 260, 118077 (2020).","journal-title":"Life Sci."},{"key":"17422_CR51","doi-asserted-by":"publisher","first-page":"988","DOI":"10.3390\/cancers12040988","volume":"12","author":"LC Holthof","year":"2020","unstructured":"Holthof, L. C. & Mutis, T. Challenges for immunotherapy in multiple myeloma: Bone marrow microenvironment-mediated immune suppression and immune resistance. Cancers (Basel) 12, 988 (2020).","journal-title":"Cancers (Basel)"},{"key":"17422_CR52","doi-asserted-by":"publisher","first-page":"1027385","DOI":"10.3389\/fimmu.2022.1027385","volume":"13","author":"LS Boussi","year":"2022","unstructured":"Boussi, L. S., Avigan, Z. M. & Rosenblatt, J. Immunotherapy for the treatment of multiple myeloma. Front Immunol. 13, 1027385 (2022).","journal-title":"Front Immunol."},{"key":"17422_CR53","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s12967-024-05888-z","volume":"23","author":"Y Dong","year":"2025","unstructured":"Dong, Y. et al. PRDX2 induces tumor immune evasion by modulating the HDAC3-Galectin-9 axis in lung adenocarcinoma cells. J. Transl. Med. 23, 81 (2025).","journal-title":"J. Transl. Med."},{"key":"17422_CR54","doi-asserted-by":"publisher","first-page":"3124","DOI":"10.7150\/jca.38057","volume":"11","author":"X Zhang","year":"2020","unstructured":"Zhang, X. et al. Peroxiredoxins and immune infiltrations in colon adenocarcinoma: Their negative correlations and clinical significances, an in silico analysis. J. Cancer 11, 3124\u20133143 (2020).","journal-title":"J. Cancer"},{"key":"17422_CR55","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1093\/carcin\/bgp127","volume":"30","author":"F Colotta","year":"2009","unstructured":"Colotta, F., Allavena, P., Sica, A., Garlanda, C. & Mantovani, A. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 30, 1073\u20131081 (2009).","journal-title":"Carcinogenesis"},{"key":"17422_CR56","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1186\/s12964-024-01544-7","volume":"22","author":"J Du","year":"2024","unstructured":"Du, J. et al. Research progress of the chemokine\/chemokine receptor axes in the oncobiology of multiple myeloma (MM). Cell Commun. Signal 22, 177 (2024).","journal-title":"Cell Commun. Signal"},{"key":"17422_CR57","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1111\/j.1365-2141.2005.05443.x","volume":"129","author":"A Pellegrino","year":"2005","unstructured":"Pellegrino, A. et al. Bone marrow endothelial cells in multiple myeloma secrete CXC-chemokines that mediate interactions with plasma cells. Br. J. Haematol. 129, 248\u2013256 (2005).","journal-title":"Br. J. Haematol."},{"key":"17422_CR58","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s41577-021-00566-3","volume":"22","author":"AM Gocher","year":"2022","unstructured":"Gocher, A. M., Workman, C. J. & Vignali, D. A. A. Interferon-\u03b3: Teammate or opponent in the tumour microenvironment?. Nat. Rev. Immunol. 22, 158\u2013172 (2022).","journal-title":"Nat. Rev. Immunol."},{"key":"17422_CR59","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.abb.2008.11.017","volume":"484","author":"B Manta","year":"2009","unstructured":"Manta, B. et al. The peroxidase and peroxynitrite reductase activity of human erythrocyte peroxiredoxin 2. Arch. Biochem. Biophys. 484, 146\u2013154 (2009).","journal-title":"Arch. Biochem. Biophys."},{"key":"17422_CR60","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.jchromb.2015.06.007","volume":"997","author":"Y Ogasawara","year":"2015","unstructured":"Ogasawara, Y. et al. A simple high performance liquid chromatography method for quantitatively determining the reduced form of peroxiredoxin 2 and the mass spectrometric analysis of its oxidative status. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 997, 136\u2013141 (2015).","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"key":"17422_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.216622","volume":"587","author":"P Chen","year":"2024","unstructured":"Chen, P. et al. Triptolide induces apoptosis and cytoprotective autophagy by ROS accumulation via directly targeting peroxiredoxin 2 in gastric cancer cells. Cancer Lett 587, 216622 (2024).","journal-title":"Cancer Lett"},{"key":"17422_CR62","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.3390\/cells12151934","volume":"12","author":"M Szeliga","year":"2023","unstructured":"Szeliga, M. & Rola, R. Conoidin A, a covalent inhibitor of peroxiredoxin 2, reduces growth of glioblastoma cells by triggering ROS production. Cells 12, 1934 (2023).","journal-title":"Cells"},{"key":"17422_CR63","doi-asserted-by":"publisher","first-page":"5210","DOI":"10.1021\/acsbiomaterials.2c01073","volume":"8","author":"A Ahmad","year":"2022","unstructured":"Ahmad, A. et al. Nanoparticle-mediated PRDX2 inhibition for specific targeting of CHK2-null colorectal cancer. ACS Biomater. Sci. Eng. 8, 5210\u20135220 (2022).","journal-title":"ACS Biomater. Sci. Eng."},{"key":"17422_CR64","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.973836","volume":"12","author":"AG Solimando","year":"2022","unstructured":"Solimando, A. G. et al. Drug resistance in multiple myeloma: Soldiers and weapons in the bone marrow niche. Front. Oncol. 12, 973836 (2022).","journal-title":"Front. Oncol."},{"key":"17422_CR65","doi-asserted-by":"publisher","first-page":"5289","DOI":"10.1038\/sj.onc.1205650","volume":"21","author":"Y Choi","year":"2002","unstructured":"Choi, Y. et al. PTEN, but not SHIP and SHIP2, suppresses the PI3K\/Akt pathway and induces growth inhibition and apoptosis of myeloma cells. Oncogene 21, 5289\u20135300 (2002).","journal-title":"Oncogene"},{"key":"17422_CR66","doi-asserted-by":"publisher","first-page":"1606804","DOI":"10.3389\/fphar.2025.1606804","volume":"16","author":"J Shi","year":"2025","unstructured":"Shi, J. et al. Ferroptosis: A novel pharmacological mechanism against multiple myeloma. Front. Pharmacol. 16, 1606804 (2025).","journal-title":"Front. Pharmacol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-17422-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-17422-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-17422-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T14:03:46Z","timestamp":1758809026000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-17422-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,25]]},"references-count":66,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["17422"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-17422-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,25]]},"assertion":[{"value":"14 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was approved by the Ethics Committee of the Second Hospital of Lanzhou University (protocol code 2024A-795 and date of approval June 28 2024). Informed consent was obtained from all subjects involved in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"32765"}}